1.
Orv Hetil
; 134(52): 2873-5, 1993 Dec 26.
Article
in Hungarian
| MEDLINE
| ID: mdl-8272354
ABSTRACT
In approximately 10 to 15 percent of congenital hemophilia A patients circulating antibodies to factor VIII appear in the blood that poses a serious problem in their treatment. A number of methods and preparations are used in the clinical practice to overcome this problem. Authors report their favourable clinical experience with the administration of polyelectrolyte-fractionated porcine factor VIII. concentrate in a hemophiliac child for the first time in Hungary and a brief review of the clinical methods in use in the management of factor VIII. inhibitors.
Subject(s)
Antibodies/immunology , Factor VIII/antagonists & inhibitors , Hemophilia A/immunology , Animals , Child , Electrolytes , Factor VIII/administration & dosage , Factor VIII/immunology , Hemophilia A/drug therapy , Humans , Male , Swine
2.
Monatsschr Kinderheilkd (1902)
; 115(5): 339-42, 1967 May.
Article
in German
| MEDLINE
| ID: mdl-5588745